Despite differing pharmacodynamics, ketamine and serotonergic psychedelics may share downstream effects crucial to their rapid and sustained antidepressant activity.
This innovation may pave the way for pharmaceuticals that act like psychedelics at the 5-HT2A receptor but don’t have hallucinogenic effects.
The names may sound familiar, but these compounds reveal more about nature’s complex chemical cocktail in toad venom.
Ketamine and psilocybin both exert rapid antidepressant effects. Could these effects be explained by a common mechanism that promotes neurogenesis?
A recent study indicates that the empathogenic effects of LSD may be independent of serotonin 2A receptor activation.
Is DMT produced in the brain? The answer remains unclear, but this 2019 study provides striking evidence supporting the neural-DMT synthesis hypothesis.
Lenz et al. have revised their bluing theory based on the data from their new study.
Sensitive to LSD? It may be in your genes.
Reviewing early research (1895-1975) on changes in visual perception.
How do psychedelics interact with the human body beyond brain cells?